State Street Corp Pardes Biosciences, Inc. Transaction History

State Street Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$1.4 - $1.95 $461,876 - $643,328	-329,912 Reduced 73.44%	119,320 $215,000
Q1 2023 May 15, 2023	BUY	$1.21 - $2.22 $4,250 - $7,798	3,513 Added 0.79%	449,232 $592,000
Q4 2022 Feb 14, 2023	BUY	$0.85 - $1.69 $20,706 - $41,170	24,361 Added 5.78%	445,719 $753,000
Q3 2022 Nov 15, 2022	BUY	$2.14 - $3.7 $182,007 - $314,685	85,050 Added 25.29%	421,358 $780,000
Q2 2022 Aug 15, 2022	BUY	$2.84 - $8.57 $721,041 - $2.18 Million	253,888 Added 308.04%	336,308 $1.03 Million
Q1 2022 May 16, 2022	BUY	$5.64 - $15.64 $464,848 - $1.29 Million	82,420 New	82,420 $595,000

5.23M

Ticker PRDS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,320,900
Description
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome ...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.